Nureca Ltd
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
- Market Cap ₹ 298 Cr.
- Current Price ₹ 312
- High / Low ₹ 448 / 198
- Stock P/E 120
- Book Value ₹ 196
- Dividend Yield 0.00 %
- ROCE 0.33 %
- ROE -0.36 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 2.89% over past five years.
- Company has a low return on equity of -1.93% over last 3 years.
- Earnings include an other income of Rs.8.49 Cr.
- Company's cost of borrowing seems high
- Working capital days have increased from 237 days to 403 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 5m | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 1 | 99 | 213 | 256 | 112 | 95 | 115 | 131 | |
| 0 | 1 | 1 | 90 | 152 | 200 | 127 | 106 | 124 | 134 | |
| Operating Profit | 0 | 0 | 0 | 10 | 62 | 56 | -15 | -11 | -10 | -3 |
| OPM % | 0% | 3% | 4% | 10% | 29% | 22% | -14% | -12% | -8% | -2% |
| 0 | 0 | 0 | 0 | 3 | 8 | 7 | 11 | 13 | 8 | |
| Interest | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 0 | 0 | 0 | 9 | 62 | 61 | -11 | -3 | -0 | 3 |
| Tax % | 50% | 33% | 26% | 26% | 26% | -23% | -25% | 46% | ||
| 0 | 0 | 0 | 6 | 47 | 45 | -8 | -2 | -1 | 2 | |
| EPS in Rs | 0.00 | 20.00 | 20.00 | 6,410.00 | 46.53 | 45.31 | -8.42 | -2.44 | -0.67 | 2.47 |
| Dividend Payout % | 0% | 0% | 0% | 4% | 7% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -23% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 165% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -5% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | -2% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 0 | 0 | 0 | 15 | 153 | 194 | 185 | 183 | 182 | 186 |
| 0 | 0 | 0 | 10 | 4 | 4 | 3 | 2 | 4 | 3 | |
| 0 | 0 | 1 | 9 | 19 | 11 | 8 | 9 | 10 | 14 | |
| Total Liabilities | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 213 |
| 0 | 0 | 0 | 1 | 3 | 10 | 8 | 6 | 8 | 13 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 | 34 | 62 | 97 | 4 | 11 |
| 0 | 0 | 1 | 33 | 181 | 175 | 136 | 101 | 194 | 189 | |
| Total Assets | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 213 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| -0 | -8 | 35 | 2 | 12 | -3 | -19 | |||
| 0 | -0 | -110 | -3 | -18 | 18 | 9 | |||
| 0 | 8 | 92 | -7 | -2 | -1 | -1 | |||
| Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365 | 87 | 65 | 47 | 0 | 4 | 14 | 7 | 14 |
| Inventory Days | 0 | 101 | 590 | 93 | 135 | 174 | 154 | 156 | 163 |
| Days Payable | 233 | 849 | 33 | 32 | 13 | 23 | 27 | 26 | |
| Cash Conversion Cycle | 365 | -45 | -195 | 107 | 103 | 165 | 145 | 136 | 151 |
| Working Capital Days | 182 | -12 | -45 | 85 | 61 | 109 | 148 | 160 | 403 |
| ROCE % | 100% | 75% | 76% | 67% | 33% | -5% | -1% | 0% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
1d - Nureca Limited has informed regarding Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Board Meeting Intimation for Declaration Of Financial Results And Other Business Matters .
10 Jan - Board meeting on Jan 17, 2026 to approve unaudited Q3 and nine-month results for period ended Dec 31, 2025.
-
Extinguishment Of Equity Shares Bought Back.
10 Jan - Extinguished 4,58,255 shares at Rs.330; tender offer Dec 18–24, 2025; post-capital 95,41,920 shares.
-
Nureca Limited Has informed Regarding
Warning Letter.
7 Jan - Received BSE and NSE warning letters for missing Stakeholders Relationship Committee meeting in FY2024-25.
-
Announcement under Regulation 30 (LODR)-Post Buyback Public Announcement
1 Jan - Board approved buyback up to ₹19,14,00,000 at ₹330 per share; announcement published Jan 01, 2026.
Annual reports
Concalls
-
Oct 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
Business Overview:[1][2]
NL is a digitally first, consumer healthcare company with presence in categories such
as home diagnostics, wellness devices, and personal fitness equipment under brands like
Dr Trust and Dr Physio. The company has 277+ Active SKUs, and 7 New Products were launched during Q1FY26